Combination Therapeutic Effect of Psoralen and Paclitaxel-Loaded Superparamagnetic Iron Oxide Nanoparticles for the Treatment of Triple-Negative Breast Cancer
International Journal of Nanomedicine · 2026
DOI: 10.2147/ijn.s641922 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026. Verfasst von Manling Du und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Paclitaxel, Triple Negative Breast Neoplasms, Magnetic Iron Oxide Nanoparticles, Ficusin. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
To overcome dose-limiting toxicity and paclitaxel (PTX) resistance in triple-negative breast cancer (TNBC) therapy, as well as the asynchronous in vivo biodistribution of PTX and psoralen (PSO) combination regimens, we developed a highly biocompatible, magnetically targeted nano-co-delivery system.
Methods
Paclitaxel/psoralen-loaded magnetic composite nanoparticles (P/P-TCNs) were fabricated via nanoprecipitation. The nanocarriers comprise a poly(lactic-co-glycolic acid) (PLGA) core co-encapsulating both therapeutic agents and superparamagnetic iron oxide nanoparticles (SPIONs), shielded by a stabilizing outer phospholipid layer.
Results
Physiochemically, P/P-TCNs exhibited uniform nanoscale dimensions, a negative surface charge, robust superparamagnetism, and synchronized drug release profiles. In vitro, P/P-TCNs significantly enhanced intracellular drug accumulation in 4T1 murine breast cancer cells, inducing profound G2/M cell cycle arrest and augmented apoptotic response. In vivo live imaging of tumor-bearing mice revealed that under an external magnetic field, P/P-TCNs selectively and efficiently accumulated at the tumor site via tail vein injection. This magnetically guided co-delivery achieved a potent tumor inhibition rate of >85%, significantly outperforming both the free drug combination and non-targeted nanoparticle controls. Furthermore, the nanoplatform demonstrated excellent hemocompatibility (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, People's Republic of China.
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou, People's Republic of China.
- Guangdong Key Laboratory of Traditional Chinese Medicine Informatization, Jinan University, Guangzhou, People's Republic of China.
- International Science and Technology Cooperation Base of Guangdong Province, Jinan University, Guangzhou, People's Republic of China.
- School of Pharmacy, Jinan University, Guangzhou, People's Republic of China.
- School of Traditional Chinese Medicine, Jinan University, Guangzhou, People's Republic of China.
ORCID-Profile: Manling Du, Mulazim Hussain Asim, Yu Cai
Zitieren
APA
Du, M., Liu, F., Wang, P., Asim, M. H., Liu, Q., Li, Q., Xie, M., Zhang, K., Yang, Z., & Cai, Y. (2026). Combination Therapeutic Effect of Psoralen and Paclitaxel-Loaded Superparamagnetic Iron Oxide Nanoparticles for the Treatment of Triple-Negative Breast Cancer. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s641922
Vancouver
Du M, Liu F, Wang P, Asim MH, Liu Q, Li Q, et al. Combination Therapeutic Effect of Psoralen and Paclitaxel-Loaded Superparamagnetic Iron Oxide Nanoparticles for the Treatment of Triple-Negative Breast Cancer. International Journal of Nanomedicine. 2026. doi:10.2147/ijn.s641922
BibTeX
@article{Du2026,
author = {Du, Manling and Liu, Fengjie and Wang, Panpan and Asim, Mulazim Hussain and Liu, Qian and Li, Qianwen and Xie, Mengjie and Zhang, Kewei and Yang, Zhenjiang and Cai, Yu},
title = {Combination Therapeutic Effect of Psoralen and Paclitaxel-Loaded Superparamagnetic Iron Oxide Nanoparticles for the Treatment of Triple-Negative Breast Cancer},
journal = {International Journal of Nanomedicine},
year = {2026},
doi = {10.2147/ijn.s641922}
}
EUVIMED